- Home
- CHT vs ONC Comparison
CHT vs ONC Comparison
Compare CHT & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHT
- ONC
- Stock Information
- Founded
- CHT 1996
- ONC 2010
- Country
- CHT Taiwan
- ONC Switzerland
- Employees
- CHT N/A
- ONC N/A
- Industry
- CHT Telecommunications Equipment
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- CHT Telecommunications
- ONC Health Care
- Exchange
- CHT Nasdaq
- ONC Nasdaq
- Market Cap
- CHT 33.6B
- ONC 37.3B
- IPO Year
- CHT 2003
- ONC N/A
- Fundamental
- Price
- CHT $43.57
- ONC $315.64
- Analyst Decision
- CHT
- ONC Strong Buy
- Analyst Count
- CHT 0
- ONC 10
- Target Price
- CHT N/A
- ONC $344.70
- AVG Volume (30 Days)
- CHT 133.1K
- ONC 229.4K
- Earning Date
- CHT 11-05-2025
- ONC 11-11-2025
- Dividend Yield
- CHT 2.98%
- ONC N/A
- EPS Growth
- CHT 3.77
- ONC N/A
- EPS
- CHT 0.17
- ONC N/A
- Revenue
- CHT $7,982,762,140.00
- ONC $4,562,002,000.00
- Revenue This Year
- CHT $4.14
- ONC $881.07
- Revenue Next Year
- CHT $2.02
- ONC N/A
- P/E Ratio
- CHT $25.90
- ONC N/A
- Revenue Growth
- CHT 3.95
- ONC 47.33
- 52 Week Low
- CHT $36.61
- ONC $170.99
- 52 Week High
- CHT $47.03
- ONC $355.30
- Technical
- Relative Strength Index (RSI)
- CHT 48.88
- ONC 44.00
- Support Level
- CHT $42.83
- ONC $309.00
- Resistance Level
- CHT $43.70
- ONC $323.75
- Average True Range (ATR)
- CHT 0.35
- ONC 9.44
- MACD
- CHT 0.04
- ONC -3.93
- Stochastic Oscillator
- CHT 63.77
- ONC 14.33
About CHT Chunghwa Telecom Co. Ltd.
Chunghwa Telecom Co Ltd is Taiwan's integrated telecom operator, providing fixed-line, wireless, and Internet and data services. The company segment consists of Consumer Business, Enterprise Business, International Business, and Others. The company generates the majority of its revenue from the Consumer Business segment. The consumer Business segment generates revenue from Mobile services, Fixed-line services, Sales, and others.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.